首页
期刊简介
编 委 会
期刊订阅
百年学会 医星璀璨
名院风范
学科风华
菁英风采
投稿须知
过刊浏览
联系我们
篇名
关键词
作者
作者单位
摘要
关键词
注册本刊作者
作者投稿查稿
专家远程审稿
编辑在线审稿
编务办公专区
主编办公专区
下载文档
《上海医学》审稿费代缴委托书
《上海医学》杂志2024年征订启事
《上海医学》期刊编审系统审稿专家使用手册
工作动态
03-05
《上海医学》杂志2024年度“春蕾杯”论文评比征文通知
06-14
创新驱动,培育人才—《上海医学》2021年度春蕾计划评审结果揭晓
01-21
《上海医学》期刊影响力指标和学科排名取得显著提升
01-20
《上海医学》恭祝大家新年快乐!
08-18
作废声明
联系方式
发行周期:
月刊
主管单位:
上海市卫生健康委员会
主办单位:
上海市医学会
编辑出版:
《上海医学》编辑部
联系地址:
上海市北京西路1623号
邮编:
200040
电话:
021-62178606
传真:
021-62178606
邮箱:
smasmj@shsma.org.cn
ISSN:
ISSN0253-9934
CN:
CN31-1366/R
收款账号:
1001255309008900719
账户名:
上海市医学会
开户行:
工商银行上海市静安寺支行
友情链接
上海市医学会
当前位置:首页 >
血清铁调素与维持性血液透析患者铁负荷及微炎症状态相关
Serum hepcidin in maintenance hemodialysis patients is associated with iron status and microinflammation
浏览(785) 下载(0)
DOI:
作者:
徐雁,邹建洲,刘中华,蒋素华,徐少伟,沈波,晋玮,滕杰,丁小强
Xu Yan, Zou Jianzhou, Liu Zhonghua, Jiang Suhua,
作者单位:
复旦大学附属中山医院
Zhongshan Hospital,Fudan University,Shanghai,
关键词:
铁调素;血液透析;炎症;贫血;铁
hepcidin; hemodialysis; inflammation; anemia; iron
摘要:
目的 探讨维持性血液透析(MHD)患者血清铁调素水平与铁负荷及微炎症状态的关系。方法 选取稳定的MHD治疗6个月以上患者48例,以体检健康人20例为对照组。采用酶联免疫吸附法(ELISA)测定血清铁调素和IL-6。用Spearman相关和线性回归分析铁调素与其他指标的相关性。结果 MHD患者血清铁调素(225.6[146.4-455.9]ng/ml vs 90.4[54.5-171.5]ng/ml, P<0.05)和IL-6(48[35.0-97.2]pg/ml vs 43.9 [26.5-51.6] pg/ml, P<0.05)皆显著高于对照组。Spearman相关分析显示血清铁调素与铁蛋白(ρ=0.892, P<0.001)、转铁蛋白饱和度(ρ=0.289, P=0.049)及IL-6(ρ=0.439, P=0.002)呈正相关;与不饱和铁结合力(ρ=-0.570,P<0.001)、总铁结合力(ρ=-0.552, P<0.001)及转铁蛋白(ρ=-0.532, P<0.001)呈负相关。线性回归分析显示铁蛋白(β=0.736,P<0.001)及总铁结合力(β=-0.204,P=0.034)与血清铁调素水平独立相关。结论 MHD患者血清铁调素水平显著升高;血清铁调素水平与MHD患者铁负荷及微炎症状态相关;ELISA方法检测铁调素可以应用于临床,结合hsCRP及铁代谢指标等指导肾性贫血中铁剂的应用。
Objective To investigate the relationship between serum hepcidin , iron status and microinflammation in maintenance hemodialysis (MHD) patients. Methods Serum was obtained from 48 MHD patients before and after undergoing hemodialysis and 20 age-matched healthy subjects. In a cross-sectional study, serum hepcidin and IL-6 levels were measured by enzyme-linked immunosorbant assay (ELISA). Spearman correlation and linear regression were used to assess the relationship between serum hepcidin levels and other laboratory parameters in MHD patients. Results Serum hepcidin(225.6[146.4-455.9]ng/ml vs 90.4[54.5-171.5]ng/ml, P<0.05) and IL-6 (48 [35.0-97.2]pg/ml vs 43.9 [26.5-51.6]pg/ml, P<0.05) levels were significantly higher in MHD patients compared with controls. In all MHD patients serum hepcidin levels correlated positively with ferritin(ρ=0.892, P<0.001), transferrin saturation(ρ=0.289, P=0.049)and IL-6(ρ=0.439, P=0.002); and negatively with unsaturated iron-binding capacity (ρ=-0.570,P<0.001), total iron-binding capacity(ρ=-0.552, P<0.001) and transferrin(ρ=-0.532, P<0.001). Linear regression analysis showed ferritin(β=0.736,P<0.001)and total iron-binding capacity(β=-0.204,P=0.034) were independently associated with serum hepcidin levels. Conclusion Serum hepcidin levels are markedly elevated in MHD patients. Serum hepcidin levels are associated with iron status and microinflammation in MHD patients.The new ELISA method for measurement of serum hepcidin is available for clinical practice.Serum hepcidin, hsCRP and markers of iron metabolism together are indicators of iron administration, and may play an important role in treating anemia in MHD patients.
点击下载DOC全文